cyto.site Home Literature

Literature / Library / plasmocyte

plasmocyte

34 pictures and 32 papers. From plasmo.site.

Gallery

Histopathology of Mott cells with Russell bodies (red arrows) compared to an almost normal plasma cell (white arrow, prominent nucleolus). Primary malignant myelomatous pleural effusion. H&E.

Mangla A, Agarwal N, Kim GJ, Catchatourian R. Clin Case Rep. 2016;4(8):803-6. DOI:10.1002/ccr3.634 · CC BY 4.0

Multinucleated plasma cell, H&E stain, extremely high magnification. An atypical form seen in some myeloma cases.

Nephron, Wikimedia Commons · CC BY-SA 3.0

A case of Multiple myeloma and the bone marrow smear shows plasma cells with eccentric nucleus, bluish cytoplasm and a pale Golgi zone. Nuclear details cannot be appreciated at this power. As for the glass slide, naked eye examination itself shows a blue staining. This is due to the romanowsky stain interacting with the fixed paraprotein on the blood/marrow film.

Dr. Roshan Nasimudeen · CC BY-SA 3.0

Examples of bone marrow samples colored by May-Grünwald-Giemsa, 1000× magnification. Plasma cell with morphologic immaturity: high nucleus/cytoplasm ratio and dispersed chromatin (A). Binucleated plasma cell and several plasma cells (PC) with dispersed chromatin (B). Bone marrow showing mature PC and a multinucleated plasma cell (C).

Pires, Barreto, Caetano et al. J Clin Med. 2025. Figure 5. · CC BY 4.0

Double staining in the trephine biopsy, CD138 staining with Dako REAL Detection System Alkaline Phosphatase kit K5005, red chromogenic presentation, MDM2 staining with DAB chromogen in brown, x400. ( A ). Newly diagnosed MM trephine biopsy, positive nuclear staining (black arrow) and negative nuclear staining (red arrow). ( B ). Trephine biopsy after the therapy, positive nuclear staining (black arrow) and negative nuclear staining (red arrow).

Stanic Damic, Grubesic, Peric et al 2025, Medicina · CC BY 4.0

Syndecan-1 (CD138) expression in normal and coeliac mucosa using monoclonal MCA2459GA. A. Expression within normal intestine, showing syndecan-1 localises predominantly to the basolateral epithelial surface (original magnification x10). B. Higher power view (x40) of normal duodenum, showing similar epithelial localisation plus the presence of scattered syndecan-1+ plasma cells within the lamina propria. C,D. Low power view (x10) of 2 cases of coeliac disease, showing retention of epithelial staining similar to controls, plus additionally a dense confluent expression within the upper lamina propria. E,F. Higher power view (x40) of the subepithelial region in these cases. The lamina propria aggregates consist of cells with dense membrane staining (plasma cells), cells with recognisable nuclei and punctate cytoplasmic staining and scattered syndecan-1+ debris (shed ectodomains)

Salvestrini, Lucas, Lionetti et al 2014, PLoS ONE · CC BY 4.0

Plasma cell ultrastructure and glycocalyx thickness in the jejunal mucosa of HC subjects and IBS-D patients. (A) Representative transmission electron microscopy images of plasma cells from HC (left panel) and IBS-D (right panel) groups. Inserts show the morphology of the RER in each group. Bar represents 1 µm. (B) Quantification of the percentage of RER area in the cytoplasm (%RER) in plasma cells in HC (n = 11) and IBS-D (n = 9) groups. (C) Correlation assessment between the %RER and the number of mitochondria per plasma cell (pooled participants, n = 20). (D) Representative transmission electron microscopy images of the glycocalyx overlying the microvilli from HC (left panel) and IBS-D (right panel) groups.

Pardo-Camacho, Ganda Mall, Martinez et al 2022, Cells · CC BY 4.0

骨髓涂片胞质轻链免疫荧光结合FISH典型荧光信号（×100）A 1q21扩增（信号模式：3R2G）；B 1p32缺失（信号模式：2R1G）；C p53缺失（信号模式：1R1G）；D IGH易位（信号模式：1R1G1F）；E IgH/FGFR3融合基因（信号模式：1R1G2F）

Shi, Yang, Guo et al 2024, Chinese Journal of Hematology · CC BY 3.0

Combined inhibition of p97 and the proteasome dramatically affects ER configuration. ( A ) RPMI 8226 myeloma cells were stained with ER Tracker Blue-White DPX following treatment for 24h with bortezomib (BTZ; 5nM), Eer1 (5µM), or both. Representative confocal microscopic images show minor ER alterations after BTZ treatment, transformation of tubule-lamellar into globular ER structures after treatment with Eer1, and widespread ER vacuolisation after dual treatment. ( B ) Representative electron microscopic images of OPM-2 cells after treatment with BTZ (5nM), Eer1 (5µM), or BTZ and Eer1, for 24h. Arrows indicate classical ER in control cells, black arrowheads indicate moderately dilated and disrupted ER in Eer1-treated cells, and open arrowheads indicate vacuolised ER with reduced ribosomes on the cytosolic ER surface. Another cell treated with Eer1 and BTZ is shown at lower magnification (right panel). Areas of dilated perinuclear space are indicated by asterisks. Nu, nucleus.

Auner, Moody, Ward et al 2013, PLoS ONE · CC BY, version not stated by the source

Ufbp1 is required for endoplasmic reticulum (ER) expansion in antibody-secreting cells. e Transmission electron microscope images of CD138 + cells sorted from LPS-stimulated B cell cultures from Ufbp1 F/F and Ufbp1 F/F CD19 cre mice. Scale bars are 1 µm. f Transmission electron microscope images of bone marrow plasma cells isolated from mice of indicated genotype. Scale bars are 1 µm.

Zhu, Bhatt, Sivaprakasam et al 2019, Nature Communications · CC BY 4.0

Haematoxylin and eosin staining of a solitary plasmacytoma of the tibia showing sheets of malignant plasma cells infiltrating bone marrow. Figure 1 from Hu X et al.

Hu, Li, Hu et al 2026, Frontiers in Oncology · CC BY 4.0

Histopathologic features of plasma cell/plasmacytic idiopathic multicentric Castleman disease. (A) Hyperplastic follicles HE stain in 4x magnification; (B) prominent interfollicular plasmacytosis; HE stain in 10x magnification (inset: HE stain higher magnification- 40x); (C) presence of plasmacytoid immunoblasts 'white circles' HE in 40x magnification (inset: Immunostain CD30-positive immunoblasts in 40x magnification). HE, hematoxylin and eosin.

Alapat, Etebari, Van Rhee et al 2026, American Journal of Clinical Pathology · CC BY 4.0

IgA+ plasma cells in human duodenal lamina propria (healthy donor). Cryostat sections stained with anti-IgA (green). IgA+ plasma cells are visible in normal lamina propria; splenectomized patients show reduced IgA+ plasma cells in the same tissue.

Carsetti R, Di Sabatino A, Rosado MM et al. Front Immunol. 2020;10:2937. PMID: 31969880 · CC BY

Plasma cell showing eccentrically placed round nucleus with cartwheel chromatin pattern. Stain not specified; chromatin clumping is consistent with Wright or Giemsa.

Department of Pathology, Calicut Medical College, Wikimedia Commons · CC BY-SA 4.0

Multinucleated plasma cell, H&E stain, high magnification. An atypical morphological variant; normal plasma cells are mononuclear.

Nephron, Wikimedia Commons · CC BY-SA 3.0

Bone marrow aspirate smears of myeloma plasma cells stained with Wright-Giemsa, 1000x. Attention heatmap overlay (blue to red) shows cells driving a deep-learning subtype classifier. Four cytogenetic subtypes shown: t(4;14), t(11;14), del(17p), gain(1q).

Gao M, Yan M, Chen X et al. Front Oncol. 2026;16:1790130. PMID: 41930202 · CC BY 4.0

Multiplex immunofluorescence staining in sequential kidney biopsies. Using two multiplex immunofluorescence assays CD38-CD138-CD27 (A, C, E, G) and CD38-CD19-CD16 (B, D, F, H) revealed changing phenotypes of immune cells across consecutive biopsies. Representative images, including magnified regions of interest with separate detection channels were shown for 2nd (A, B), 3rd (C, D) and 4th (E, F) biopsies using a Zeiss LSM710 confocal laser scanning microscope (Zeiss, Oberkochen, Germany) with a 20x objective. From every section, 4-5 representative images per biopsy were subsequently analyzed for the frequency of immune cell subsets using QuPath software showing the mean cell counts per mm 2. White arrows indicate CD16+ cells (B). *in addition, CD38+ material colocalized with diffuse DAPI (4',6-diamidino-2-phenylindole) staining, indicating broken or lysed CD38+ cells.

de Fallois, Baatz, Kruger et al 2026, Frontiers in Immunology · CC BY 4.0

Detection of structures surrounded by four membranes in the "apicoplast-minus" parasites by immuno-EM. (A-C) ACP-positive structures surrounded by a single membrane (short black arrows). (D-F) ACP-positive structures surrounded by four membranes (long black arrows). (G) negative control with no primary antibody. Bars = 500 nm. Data are representative from two independent experiments.

Xu, Nwankwo, Prigge et al 2026, mSphere · CC BY 4.0

Detection of structures surrounded by four membranes in the "apicoplast-minus" parasites by immuno-EM. (A-C) ACP-positive structures surrounded by a single membrane (short black arrows). (D-F) ACP-positive structures surrounded by four membranes (long black arrows). (G) negative control with no primary antibody. Bars = 500 nm. Data are representative from two independent experiments.

Xu, Nwankwo, Prigge et al 2026, mSphere · CC BY 4.0

Expression of SLFN11, CD138, and Ki-67 in multiple myeloma (MM) patient samples and normal bone marrow. A, Representative dual immunohistochemical staining for CD138 (blue, membrane) and SLFN11 (brown, nuclear) in bone marrow samples from patients with MM. Patients 1 and 2 are primary (P; newly diagnosed), whereas patient 3 (R) represents a sample from a recurrent patient. 81%-98% CD138-positive myeloma cells express SLFN11. B, Dual immunohistochemical staining for CD138 (blue) and SLFN11 (brown) in normal bone marrow. Left, low magnification. Right, high magnification of the same field. Normal bone marrow contains 5.5%-6.8% plasma cells, of which 72%-85% demonstrate SLFN11 positivity, indicating that SLFN11 expression is an intrinsic feature of NPCs. Scale bars, 50 um (left) and 10 um (right). C, Representative dual immunohistochemical staining for CD138 (blue) and Ki-67 (brown, nuclear) to assess proliferative activity. Left and middle, patient 1 at primary diagnosis (P) and third relapse (R3), respectively. Right, normal bone marrow. The PCPI, defined as the percentage of CD138-positive cells coexpressing Ki-67, is markedly elevated in myeloma specimens compared with normal bone marrow, with further increases observed at relapse. Scale bars, 10 um. BM, bone marrow.

Arakawa, Taniyama, Suzuki et al 2026, Cancer Research Communications · CC BY 4.0

Expression of SLFN11, CD138, and Ki-67 in multiple myeloma (MM) patient samples and normal bone marrow. A, Representative dual immunohistochemical staining for CD138 (blue, membrane) and SLFN11 (brown, nuclear) in bone marrow samples from patients with MM. Patients 1 and 2 are primary (P; newly diagnosed), whereas patient 3 (R) represents a sample from a recurrent patient. 81%-98% CD138-positive myeloma cells express SLFN11. B, Dual immunohistochemical staining for CD138 (blue) and SLFN11 (brown) in normal bone marrow. Left, low magnification. Right, high magnification of the same field. Normal bone marrow contains 5.5%-6.8% plasma cells, of which 72%-85% demonstrate SLFN11 positivity, indicating that SLFN11 expression is an intrinsic feature of NPCs. Scale bars, 50 um (left) and 10 um (right). C, Representative dual immunohistochemical staining for CD138 (blue) and Ki-67 (brown, nuclear) to assess proliferative activity. Left and middle, patient 1 at primary diagnosis (P) and third relapse (R3), respectively. Right, normal bone marrow. The PCPI, defined as the percentage of CD138-positive cells coexpressing Ki-67, is markedly elevated in myeloma specimens compared with normal bone marrow, with further increases observed at relapse. Scale bars, 10 um. BM, bone marrow.

Arakawa, Taniyama, Suzuki et al 2026, Cancer Research Communications · CC BY 4.0

SEC24A&B-depleted secretory MM cells accumulate misfolded proteins and increase the size of the ER. a, b TPE-MI fluorescence was measured by flow cytometry after staining cells with 50 uM TPE-MI for 30 min. The data show the percentage change in median fluorescence intensity compared to the siRNA control condition for a AMO-1 and b NCI-H929 cells. Means +/-SEM are shown (n = 3-5 measurements). Statistical significance was measured with one-way ANOVA followed by Dunnett's test (*** P <0.001; * P < 0.05). Representative histograms are shown on the right side of each graph with the same color code. c After 32 h of siRNA-mediated transfection of MM cell lines, cells were treated with vehicle (DMSO), 2 uM KIRA6, or 40 uM STF083010 for an additional 16 h. Cell viability was then assessed using the CellTiter-Glo assay. Data represent the mean of three independent experiments +/-SEM. *** P < 0.001; * P <0.05, as calculated using a two-way ANOVA and Tukey post hoc test. d After 48 h of SEC24A&B co-knockdown, cells were stained with calnexin to label the ER, and confocal images of 3D reconstructions of the ER were acquired. Image stacks with 0.1 um steps along the z-axis were used to analyze ER morphology using ImageJ 3D-suite. ER volume was normalized to the corresponding cell volume. Quantification was performed from three independent experiments. Data are presented as violin plots. Dots represent individual cells, AMO-1 (blue) and NCI-H929 (pink), n > 50 for each condition. The right panel shows a representative set of images for each cell type. Scale bar, 10 um

Horzum, Oberacher, Haun et al 2026, Signal Transduction and Targeted Therapy · CC BY 4.0

Loaded ASCs localize in the perivascular space of the BMOC. B cell subpopulations in human donor tissue are shown as percentages ( A ) and counts per 100,000 cells ( B ). ( C ) A schematic of lymphoid organoids displays the coculture of tonsil cells with CD40L and stromal cells in a PEG-4MAL synthetic hydrogel (top). Bottom: Representative ASC populations from day-0 tonsil samples and after 15 days of culture in the lymphoid organoids are illustrated. ( D ) Time-lapse microscopy captures loaded B cells (magenta) entering the central channel from the media channels and moving through the vessels (white), with a single cell tracked by a blue arrow. Scale bars, 500 um. ( E ) Loaded B cells (cyan) aggregate near the vessels (white), with the scale bar measuring 100 um. The zoomed areas highlight B cells outside (left) and inside (right) the vessels. ( F ) Representative Z-slices show B cell localization around niche markers: left: YZ view, top: XZ view, and center: XY view. Scale bars, 80 um. Yellow arrows highlight B cells that are located near pink CXCL12 or VCAM-1 staining. ( G ) Distance of ASCs from CXCL12 and VCAM-1 compared to randomized control distribution using Welch's unpaired t test.

Kramer, Dai, Corbin et al 2026, Science Advances · CC BY 4.0

IFI27 induces myeloma cell pyroptosis in a GSDME-dependent manner. (A, B) OCI-My5 and OPM2 cells were infected with increased IFI27 lentivirus as indicated, followed by pyroptosis morphology determination (A), and culture media were subjected to LDH measurement (B) (n = 3), after 72 h of overexpression of IFI27 with a concentration gradient. Scale bar, 20 um. (C) Myeloma cell lines were infected with IFI27 lentivirus for 72 h before cell lysates were prepared for IB assays against different GSDMs. (D-G) GSDME was stably knocked down from OCI-My5 and OPM2 cells by its specific sgRNA, followed by infection with IFI27 lentivirus. Seventy-two h later, cells were performed to phase-contrast microscopy analysis (D) and statistical analysis on pyroptotic cells (E); cell lysates were prepared for IB assays (F) and culture media were subjected to LDH release measurement (G) (n = 5). Scale bar, 20 um. (H-J) RPMI-8226 cells were infected with WT or D270A GSDME lentivirus alone or with IFI27 lentivirus for 72 h for IB assays (H), pyroptotic analysis on phase-contrast microscopy (I), and statistical analysis of pyroptosis rate of cells (J) (n = 6). Scale bar, 20 um. (K, L) Primary myeloma cells were infected with IFI27 lentivirus for 72 h followed by IB assays using cell lysates (K) and phase-contrast microscopy assays (L). Scale bar, 10 um. **, p < 0.01; ***, p < 0.001. EV, empty virus.

Cui, Sun, Liu et al 2026, Advanced Science · CC BY 4.0

Bone marrow biopsy H&E stain (x40 objective). Immunostaining was positive for CD138 (x40 objective), cyclin D1 (x40 objective), MUM1 (x20 objective), and negative for kappa and lambda staining (x40 objective).

Xu, Proctor 2026, EJHaem · CC BY 4.0

(A) Blood film (x100 objective) showed large atypical plasma cells, some with prominent nucleoli and plasmablast morphology; (B) bone marrow aspirate (x40 objective) showed background staining and heavy infiltration of plasma cells with atypical binucleated forms; (C) peripheral blood immunophenotyping showing a population (green colour) of cells that are CD45-CD5-CD19-CD20-CD56-CD33-CD23-Ig-.

Xu, Proctor 2026, EJHaem · CC BY 4.0

Histopathology of the rib lesion shows dense sheets of plasma cells with eccentric nuclei, clumped chromatin, and a perinuclear hof, consistent with a monoclonal plasma cell infiltrate (H&E, original magnification x20).

Fang, Tian, Tang et al 2026, Frontiers in Medicine · CC BY 4.0

Expression of SLFN11, CD138, and Ki-67 in multiple myeloma (MM) patient samples and normal bone marrow. A, Representative dual immunohistochemical staining for CD138 (blue, membrane) and SLFN11 (brown, nuclear) in bone marrow samples from patients with MM. Patients 1 and 2 are primary (P; newly diagnosed), whereas patient 3 (R) represents a sample from a recurrent patient. 81%-98% CD138-positive myeloma cells express SLFN11. B, Dual immunohistochemical staining for CD138 (blue) and SLFN11 (brown) in normal bone marrow. Left, low magnification. Right, high magnification of the same field. Normal bone marrow contains 5.5%-6.8% plasma cells, of which 72%-85% demonstrate SLFN11 positivity, indicating that SLFN11 expression is an intrinsic feature of NPCs. Scale bars, 50 um (left) and 10 um (right). C, Representative dual immunohistochemical staining for CD138 (blue) and Ki-67 (brown, nuclear) to assess proliferative activity. Left and middle, patient 1 at primary diagnosis (P) and third relapse (R3), respectively. Right, normal bone marrow. The PCPI, defined as the percentage of CD138-positive cells coexpressing Ki-67, is markedly elevated in myeloma specimens compared with normal bone marrow, with further increases observed at relapse. Scale bars, 10 um. BM, bone marrow.

Arakawa, Taniyama, Suzuki et al 2026, Cancer Research Communications · CC BY 4.0

Expression of SLFN11, CD138, and Ki-67 in multiple myeloma (MM) patient samples and normal bone marrow. A, Representative dual immunohistochemical staining for CD138 (blue, membrane) and SLFN11 (brown, nuclear) in bone marrow samples from patients with MM. Patients 1 and 2 are primary (P; newly diagnosed), whereas patient 3 (R) represents a sample from a recurrent patient. 81%-98% CD138-positive myeloma cells express SLFN11. B, Dual immunohistochemical staining for CD138 (blue) and SLFN11 (brown) in normal bone marrow. Left, low magnification. Right, high magnification of the same field. Normal bone marrow contains 5.5%-6.8% plasma cells, of which 72%-85% demonstrate SLFN11 positivity, indicating that SLFN11 expression is an intrinsic feature of NPCs. Scale bars, 50 um (left) and 10 um (right). C, Representative dual immunohistochemical staining for CD138 (blue) and Ki-67 (brown, nuclear) to assess proliferative activity. Left and middle, patient 1 at primary diagnosis (P) and third relapse (R3), respectively. Right, normal bone marrow. The PCPI, defined as the percentage of CD138-positive cells coexpressing Ki-67, is markedly elevated in myeloma specimens compared with normal bone marrow, with further increases observed at relapse. Scale bars, 10 um. BM, bone marrow.

Arakawa, Taniyama, Suzuki et al 2026, Cancer Research Communications · CC BY 4.0

Expression of SLFN11, CD138, and Ki-67 in multiple myeloma (MM) patient samples and normal bone marrow. A, Representative dual immunohistochemical staining for CD138 (blue, membrane) and SLFN11 (brown, nuclear) in bone marrow samples from patients with MM. Patients 1 and 2 are primary (P; newly diagnosed), whereas patient 3 (R) represents a sample from a recurrent patient. 81%-98% CD138-positive myeloma cells express SLFN11. B, Dual immunohistochemical staining for CD138 (blue) and SLFN11 (brown) in normal bone marrow. Left, low magnification. Right, high magnification of the same field. Normal bone marrow contains 5.5%-6.8% plasma cells, of which 72%-85% demonstrate SLFN11 positivity, indicating that SLFN11 expression is an intrinsic feature of NPCs. Scale bars, 50 um (left) and 10 um (right). C, Representative dual immunohistochemical staining for CD138 (blue) and Ki-67 (brown, nuclear) to assess proliferative activity. Left and middle, patient 1 at primary diagnosis (P) and third relapse (R3), respectively. Right, normal bone marrow. Scale bars, 10 um. BM, bone marrow.

Arakawa, Taniyama, Suzuki et al 2026, Cancer Research Communications · CC BY 4.0

Expression of SLFN11, CD138, and Ki-67 in multiple myeloma (MM) patient samples and normal bone marrow. A, Representative dual immunohistochemical staining for CD138 (blue, membrane) and SLFN11 (brown, nuclear) in bone marrow samples from patients with MM. Patients 1 and 2 are primary (P; newly diagnosed), whereas patient 3 (R) represents a sample from a recurrent patient. 81%-98% CD138-positive myeloma cells express SLFN11. B, Dual immunohistochemical staining for CD138 (blue) and SLFN11 (brown) in normal bone marrow. Left, low magnification. Right, high magnification of the same field. Normal bone marrow contains 5.5%-6.8% plasma cells, of which 72%-85% demonstrate SLFN11 positivity, indicating that SLFN11 expression is an intrinsic feature of NPCs. Scale bars, 50 um (left) and 10 um (right). C, Representative dual immunohistochemical staining for CD138 (blue) and Ki-67 (brown, nuclear) to assess proliferative activity. Left and middle, patient 1 at primary diagnosis (P) and third relapse (R3), respectively. Right, normal bone marrow. The PCPI, defined as the percentage of CD138-positive cells coexpressing Ki-67, is markedly elevated in myeloma specimens compared with normal bone marrow, with further increases observed at relapse. Scale bars, 10 um. BM, bone marrow.

Arakawa, Taniyama, Suzuki et al 2026, Cancer Research Communications · CC BY 4.0

SLFN11-dependent suppression of rRNA synthesis by BTZ. A, Representative immunofluorescence images showing total SLFN11 (green, no preextraction) and DAPI (blue) in parental and SLFN11 KO KMS-34 cells. Scale bars, 10 um. B, SLFN11 immunoblots for whole-cell lysates from WT and SLFN11 KO clones of KMS-34 cells. C, Representative immunofluorescence images showing EU incorporation (green) and DAPI (blue). Top, KMS-34 cells. Bottom, KMS-27 cells. WT and SLFN11 KO clones were treated with BTZ (0.1 umol/L) for indicated time points. Scale bars, 5 um. D, Quantification of EU signal intensities in individual cells. Mean +/- SEM are shown. ****, P < 0.0001 (one-way ANOVA).

Arakawa, Taniyama, Suzuki et al 2026, Cancer Research Communications · CC BY 4.0

Normal morphological structure of Cd23-Cre Bhlha15 fl/fl plasma cells. (A) Electron microscopic analysis of bone marrow PCs of the indicated genotypes, which were sorted as B220int CD28+ CD138+ Lin- cells, fixed and processed as described in Methods. The scale bars indicate 2 um. The cells surrounding the PCs are erythrocytes. (B) Quantification of the content of endoplasmic reticulum (ER) in PCs of the different genotypes. The ER content was manually determined by using the Fiji software. Each dot represents one PC. In total, 33 Xbp1 fl/fl PCs, 14 Cd23-Cre Xbp1 fl/fl PCs, and 31 Cd23-Cre Bhlha15 fl/fl PCs were analyzed. (C) Staining of splenic PCs (TACI+ CD138+) of the indicated genotypes with Lyso-Tracker at day 7 after NP-KLH immunization (left). The MFI values of the Lyso-Tracker staining (right) are shown for all PCs analyzed in 3 independent experiments. Each dot represents one mouse. Statistical data (B, C) are shown as mean values with SEM and were analyzed with the unpaired Student's t test; * P < 0.05; **** P < 0.0001.

Wohner, Pinter, Bonelt et al 2022, Frontiers in Immunology · CC BY 4.0

H&E staining of BM biopsy showing interstitial lymphocytic infiltrates. (A) 20x magnification. (B) 40x magnification.

Sternbach, Bishara, Gertz et al 2026, Case Reports in Hematology · CC BY 4.0

Papers

  1. Luo H, Han G, Tian Z, Zhu C, Chen Z, Xu Q, et al. IgG4-related kidney disease mimicking renal cell carcinoma: a case report and literature review. Front Med (Lausanne). 2026;13:1933790. PMID: 42835178.
  2. Lei Z, Zheng N, Wang L, Fang L, Wu X. Epstein-Barr virus-associated inflammatory polyp of the proximal cervical trachea causing central airway obstruction: a case report. Front Med (Lausanne). 2026;13:1940485. PMID: 42755576.
  3. Kramer L, Dai Z, Corbin J, Ringquist R, Bhatia E, Petersen I, et al. Ex vivo bone marrow subniches influence the fate of human antibody-secreting cells. Sci Adv. 2026;12:eadz3976. PMID: 42726849.
  4. Cui Y, Sun Y, Liu Z, Lai X, Zhao Y, Wang Y, et al. IFI27 and BAX are Essential for GSDME-Mediated Myeloma Cell Pyroptosis. Adv Sci (Weinh). 2026:e77164. PMID: 42669156.
  5. Ge Y, Xu B, Wang Z, Zhao Y. Contrast-enhanced ultrasound-guided biopsy and perfusion monitoring for bladder involvement in relapsed multiple myeloma: a case report. Front Oncol. 2026;16:1892543. PMID: 42614299.
  6. de Fallois J, Baatz S, Krüger BM, Dilz LM, Boldt A, Beck J, et al. Type-II-CD20-targeted therapy for CD38 antibody-refractory antibody-mediated rejection after kidney transplantation: a case report. Front Immunol. 2026;17:1867833. PMID: 42591348.
  7. Zou LL, Ma YY. Multimodal imaging diagnosis of multiple myeloma with renal involvement: a case report. Front Oncol. 2026;16:1881507. PMID: 42523529.
  8. Lu F, Li F, Zhan H, Huang Y, Huang R, Jiang X, et al. CD19-negative non-IgM type lymphoplasmacytic lymphoma: a case report and literature review. Front Oncol. 2026;16:1809955. PMID: 42516131.
  9. Babić A, Franić Šimić I, Knežević J, Gjadrov Kuveždić K, Ilić I, Ivek I, et al. Concurrent B-cell acute lymphoblastic leukemia and plasma cell neoplasm with plasmablastic features supporting divergent evolution from a shared precursor: a case report. Front Oncol. 2026;16:1886626. PMID: 42500292.
  10. Yang XQ, Liu TT, Liu HY, Li L. Coexistence of lymphoplasmacytic lymphoma and multiple myeloma: a case report and review of literature. Front Oncol. 2026;16:1789073. PMID: 42459328.
  11. Arakawa Y, Taniyama D, Suzuki K, Yano S, Pommier Y. Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib. Cancer Res Commun. 2026;6:1777-1793. PMID: 42424601.
  12. Horzum U, Oberacher H, Haun M, Geley S, Roman-Trufero M, Auner H, et al. Targeting endoplasmic reticulum export disrupts metabolic resilience in multiple myeloma. Signal Transduct Target Ther. 2026;11:262. PMID: 42409778.
  13. Xu W, Nwankwo I, Prigge ST, Ke H. Inheritance of four-membrane-bound structures in the "apicoplast-minus" Plasmodium falciparum. mSphere. 2026;11:e0002426. PMID: 42370693.
  14. Li Y, Huang L, He W, Wang X, Tang N, Zhu D, et al. Case Report: First occurrence of smoldering multiple myeloma in activated phosphoinositide 3-Kinase δ syndrome. Front Oncol. 2026;16:1859289. PMID: 42370161.
  15. Sternbach N, Bishara S, Gertz MA, Vaxman I. Waldenström Macroglobulinemia Presenting With Hepatic Lesions: Case Report and Literature Review. Case Rep Hematol. 2026;2026:9908044. PMID: 42282257.
  16. Gao M, Yan X, Chen L, Ouyang G, Liu Y, Chen S. Morphology-based cytogenetic risk prediction in multiple myeloma from bone marrow smears. Front Oncol. 2026;16:1790130. PMID: 41930202.
  17. Sun R, Pu D, Wan R, Yu X, Chen H, Yu M. Extramedullary plasmacytoma of the thyroid: a case report and literature review. Front Oncol. 2026;16:1752447. PMID: 41907596.
  18. Fang Z, Tian Z, Tang J, Lei B, He Z, Zhu C, et al. A case of solitary bone plasmacytoma to multiple myeloma: a case report. Front Med (Lausanne). 2026;13:1774242. PMID: 41822898.
  19. Alapat DV, Etebari P, Van Rhee F. Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist's perspective. Am J Clin Pathol. 2026;165:aqaf134. PMID: 41774910.
  20. Hu X, Li D, Hu X, Li S, Wang P. Solitary plasmacytoma of the tibia: literature review and case report. Front Oncol. 2026;16:1503479. PMID: 41646436.
  21. Xu K, Proctor I. Non-Secretory Myeloma With Non-Producing Phenotype Presented as Plasma Cell Leukaemia With Plasmablast Morphology. EJHaem. 2026;7:e70224. PMID: 41568011.
  22. Stanić Damić M, Grubešić A, Perić Z, Jonjić N, Seili-Bekafigo I, Hauser G, et al. The Association and Significance of MDM2 and NF-κB Protein Expression in Multiple Myeloma. Medicina (Kaunas). 2025;61:1948. PMID: 41303785.
  23. Pires AM, Barreto JP, Caetano J, Soares MJ, Geraldes C, Fernandes B, et al. Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations. J Clin Med. 2025;14:7115. PMID: 41096195.
  24. Shi Y, Yang H, Guo R, Guo Z, Li JY, Wu YJ, et al. [Cytoplasmic light-chain immunofluorescence combined with FISH in bone marrow smears to detect cytogenetic abnormalities in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2024;45:566-570. PMID: 39134488.
  25. Avramidou E, Gkantaras A, Dermitzakis I, Sapalidis K, Manthou ME, Theotokis P. Histological Alterations in Hashimoto's Disease: A Case-Series Ultrastructural Study. Medicines (Basel). 2023;10:51. PMID: 37755241.
  26. Wöhner M, Pinter T, Bönelt P, Hagelkruys A, Kostanova-Poliakova D, Stadlmann J, et al. The Xbp1-regulated transcription factor Mist1 restricts antibody secretion by restraining Blimp1 expression in plasma cells. Front Immunol. 2022;13:859598. PMID: 36618345.
  27. Pardo-Camacho C, Ganda Mall JP, Martínez C, Pigrau M, Expósito E, Albert-Bayo M, et al. Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations. Cells. 2022;11:2046. PMID: 35805133.
  28. Carsetti R, Di Sabatino A, Rosado MM, Cascioli S, Piano Mortari E, Milito C, et al. Lack of Gut Secretory Immunoglobulin A in Memory B-Cell Dysfunction-Associated Disorders: A Possible Gut-Spleen Axis. Front Immunol. 2019;10:2937. PMID: 31969880.
  29. Zhu H, Bhatt B, Sivaprakasam S, Cai Y, Liu S, Kodeboyina SK, et al. Ufbp1 promotes plasma cell development and ER expansion by modulating distinct branches of UPR. Nat Commun. 2019;10:1084. PMID: 30842412.
  30. Mangla A, Agarwal N, Kim GJ, Catchatourian R. Primary malignant myelomatous pleural effusion. Clin Case Rep. 2016;4:803-6. PMID: 27525090.
  31. Salvestrini C, Lucas M, Lionetti P, Torrente F, James S, Phillips AD, et al. Matrix expansion and syncytial aggregation of syndecan-1+ cells underpin villous atrophy in coeliac disease. PLoS One. 2014;9:e106005. PMID: 25198673.
  32. Auner HW, Moody AM, Ward TH, Kraus M, Milan E, May P, et al. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PLoS One. 2013;8:e74415. PMID: 24069311.

cytology · hub